Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures.
anxiety
depression
eslicarbazepine acetate
focal seizures
psychiatric
psychotropic
Journal
Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
28
03
2022
accepted:
28
07
2022
pubmed:
1
8
2022
medline:
3
12
2022
entrez:
31
7
2022
Statut:
ppublish
Résumé
Eslicarbazepine acetate (ESL) is a once-daily (QD), oral anti-seizure medication for the treatment of focal (partial-onset) seizures. Here, we evaluate risk factors for the development of psychiatric treatment-emergent adverse events (TEAEs) in clinical trials of adjunctive ESL in adults with focal seizures. This post-hoc analysis evaluated data pooled from three Phase III, randomized, double-blind, placebo-controlled trials (BIA-2093-301, -302, -304). After an 8-week baseline period, patients were randomized equally to receive placebo, ESL 400 mg (not reported here), 800 mg, or 1200 mg QD (up to 2-week titration; 12-week maintenance; optional open-label extension [OLE]). Incidences of psychiatric TEAEs were evaluated according to three separate criteria: medical history of psychiatric disorders (yes/no); baseline use of psychotropic drugs (yes/no); Montgomery-Åsberg Depression Rating Scale (MADRS) score at baseline (0-6: normal; 7-19: mild depression; 20-34: moderate depression). The analysis populations comprised 1251 patients for the controlled study period and 1137 patients for the 1-year OLE. Psychiatric TEAE incidence was similar between patients taking ESL and placebo in the controlled and OLE study periods and was not related to ESL dose. Psychiatric TEAEs generally occurred more frequently in patients with a medical history of psychiatric disorders, using psychotropic drugs, or with depressive symptoms than in those without a history, not using psychotropic drugs, or with no depressive symptoms. Depression and anxiety were the most frequently reported psychiatric TEAEs. Overall, in clinical trials of ESL in adults with focal seizures, incidences of psychiatric events were not statistically different between patients taking ESL and placebo, were not related to ESL dose, and generally occurred more frequently in patients with baseline psychiatric symptoms or a history of psychiatric disorders. Long-term exposure to ESL was not associated with a marked increase in the incidence of psychiatric TEAEs.
Identifiants
pubmed: 35908275
doi: 10.1002/epi4.12635
pmc: PMC9712463
doi:
Substances chimiques
Anticonvulsants
0
Dibenzazepines
0
eslicarbazepine acetate
BEA68ZVB2K
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
616-632Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2022 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Nat Rev Neurol. 2016 Feb;12(2):106-16
pubmed: 26782334
Epilepsy Behav. 2017 Jul;72:127-134
pubmed: 28575761
Epilepsia Open. 2022 Dec;7(4):616-632
pubmed: 35908275
Curr Treat Options Neurol. 2017 Oct 19;19(12):44
pubmed: 29046989
Transl Psychiatry. 2018 Aug 16;8(1):157
pubmed: 30115911
Trends Neurosci. 2012 Jan;35(1):36-46
pubmed: 22217451
Geriatr Psychol Neuropsychiatr Vieil. 2018 Jun 1;16(2):181-188
pubmed: 29877186
Pharmacol Rep. 2016 Oct;68(5):1084-92
pubmed: 27634589
Epilepsia. 2009 Mar;50(3):454-63
pubmed: 19243424
Seizure. 2017 Jul;49:79-82
pubmed: 28532711
Epilepsy Behav. 2019 Nov;100(Pt A):106439
pubmed: 31574428
Expert Opin Pharmacother. 2019 Jan;20(1):41-45
pubmed: 30428279
Epilepsy Behav. 2020 Jan;102:106669
pubmed: 31785486
Drugs Aging. 2008;25(11):955-62
pubmed: 18947263
World J Biol Psychiatry. 2018 Feb;19(1):2-58
pubmed: 29098925
Epilepsy Res. 2010 May;89(2-3):278-85
pubmed: 20299189
JAMA Neurol. 2019 Apr 1;76(4):440-446
pubmed: 30688969
Lancet Neurol. 2012 Sep;11(9):792-802
pubmed: 22832500
Am J Health Syst Pharm. 2009 Mar 15;66(6):541-61
pubmed: 19265183
Epilepsia. 2017 Jul;58(7):1123-1130
pubmed: 28464309
Epilepsy Behav. 2011 May;21(1):1-11
pubmed: 21498130
Epilepsy Behav. 2018 May;82:119-127
pubmed: 29604484
Epilepsia. 2015 Feb;56(2):244-53
pubmed: 25528898